A common mutation in a key enzyme involved in alcohol metabolism may increase damage in cells obtained from individuals with Alzheimer’s disease and in mice.
Browsing: Cognitive/neurodegenerative disorders
A team of researchers discovered how amyloid-β and tau proteins work together to disrupt cell communication in the brains of individuals with Alzheimer’s disease.
At the Clinical Trials on Alzheimer’s Disease Congress this week, Biogen (MA, USA) has provided a detailed report on the latest aducanumab results, including why there was such a difference in the results between ENGAGE and EMERGE.
A recent set of studies reports how blood–brain barrier leakage may affect inflammation in the brain, potentially leading to acceleration of neurological aging in mice.
Artificial neurons have been developed in a first-of-its-kind achievement that closely resemble biological neurons, mimicking their responses to a range of stimulations.
At SfN Neuroscience 2019, we had the brilliant opportunity of interviewing Hemraj Dodiya about sex-specific effects of microbiome perturbations in an Alzheimer’s mouse model.
The US FDA-approved anti-inflammatory drug cromolyn sodium has been demonstrated to delay disease progression in an ALS mouse model.
A new study has revealed that specific patterns in brain activity can indicate whether a young mouse will develop Alzheimer’s-like memory deficits in old age.
Preclinical data has demonstrated that an oral small molecule drug could inhibit the formation of neurotoxic tau oligomers in an animal model most relevant to Alzheimer’s disease.
A study of more than 1000 elderly patients has revealed that there are no links between statin medication and cognitive decline.